These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20925049)

  • 61. HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore.
    Goh KS; Kapoor R; Lee CC; Ng CY; Leong KP
    Ann Acad Med Singap; 2019 Apr; 48(4):133-138. PubMed ID: 31131386
    [No Abstract]   [Full Text] [Related]  

  • 62. HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?
    To SW; Chen JH; Wong KH; Chan KC; Tsang OT; Yam WC
    Int J STD AIDS; 2013 Jan; 24(1):50-2. PubMed ID: 23512513
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis.
    Tangamornsuksan W; Lohitnavy O; Kongkaew C; Chaiyakunapruk N; Reisfeld B; Scholfield NC; Lohitnavy M
    J Pharm Pharm Sci; 2015; 18(1):68-76. PubMed ID: 25877443
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comprehensive evaluation of two HLA-B17 monoclonal antibodies for flow cytometry-based HLA-B57/B58 screening prior to abacavir prescription.
    Stevens R; Coates E; Street J; Cook E; Darke C
    Int J Immunogenet; 2013 Aug; 40(4):311-5. PubMed ID: 23280011
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Development of new HLA-B*3505 genotyping method using Invader assay.
    Hosono N; Chantarangsu S; Kiyotani K; Takata S; Tsuchiya Y; Mahasirimongkol S; Chantratita W; Mushiroda T; Nakamura Y; Kubo M
    Pharmacogenet Genomics; 2010 Oct; 20(10):630-3. PubMed ID: 20679961
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development of multiplex pyrosequencing for HLA-B*57:01 screening using single nucleotide polymorphism haplotype.
    Sankuntaw N; Chantarangsu S; Chantratita W; Sungkanuparph S; Kiertiburanakul S; Lulitanond V
    J Clin Pharm Ther; 2014 Oct; 39(5):545-50. PubMed ID: 24861233
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients.
    Rodríguez-Sáinz C; Valor L; Hernández DC; Gil J; Carbone J; Pascual-Bernaldez M; Rodríguez-Alcántara F; Martínez I; Vicario JL; Mallal S; Fernández-Cruz E
    HIV Clin Trials; 2013; 14(4):160-4. PubMed ID: 23924588
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701.
    Waters LJ; Mackie NE; Pozniak A; Winston A
    Clin Infect Dis; 2007 Nov; 45(9):1243-4; author reply 1244-5. PubMed ID: 17918094
    [No Abstract]   [Full Text] [Related]  

  • 69. HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience.
    Ruiz-Iruela C; Padullés-Zamora N; Podzamczer-Palter D; Alonso-Pastor A; Candás-Estébanez B; Alía-Ramos P; Padró-Miquel A
    Pharmacogenet Genomics; 2016 Aug; 26(8):390-6. PubMed ID: 27195528
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population.
    Zucman D; Truchis Pd; Majerholc C; Stegman S; Caillat-Zucman S
    J Acquir Immune Defic Syndr; 2007 May; 45(1):1-3. PubMed ID: 17356469
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Abacavir hypersensitivity reaction in primary HIV infection.
    Stekler J; Maenza J; Stevens C; Holte S; Malhotra U; McElrath MJ; Corey L; Collier AC
    AIDS; 2006 Jun; 20(9):1269-74. PubMed ID: 16816555
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity.
    Kostenko L; Kjer-Nielsen L; Nicholson I; Hudson F; Lucas A; Foley B; Chen K; Lynch K; Nguyen J; Wu AH; Tait BD; Holdsworth R; Mallal S; Rossjohn J; Bharadwaj M; McCluskey J
    Tissue Antigens; 2011 Jul; 78(1):11-20. PubMed ID: 21501118
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa.
    Kolou M; Poda A; Diallo Z; Konou E; Dokpomiwa T; Zoungrana J; Salou M; Mba-Tchounga L; Bigot A; Ouedraogo AS; Bouyout-Akoutet M; Ekouevi DK; Eholie SP
    BMC Immunol; 2021 Jul; 22(1):48. PubMed ID: 34294032
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Detection of HLA-B*58:01, the susceptible allele for allopurinol-induced hypersensitivity, by loop-mediated isothermal amplification.
    Kwok J; Kwong KM
    Br J Dermatol; 2013 Mar; 168(3):526-32. PubMed ID: 23066948
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data.
    Dello Russo C; Lisi L; Fabbiani M; Gagliardi D; Fanti I; Di Giambenedetto S; Cauda R; Navarra P
    Pharmacogenomics; 2014 Feb; 15(3):319-27. PubMed ID: 24533711
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01.
    Sousa-Pinto B; Pinto-Ramos J; Correia C; Gonçalves-Costa G; Gomes L; Gil-Mata S; Araújo L; Delgado L
    J Allergy Clin Immunol; 2015 Oct; 136(4):1092-4.e3. PubMed ID: 25934581
    [No Abstract]   [Full Text] [Related]  

  • 77. Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative.
    Chen SJ; Yang SP; Hung CC; Fung CP
    AIDS; 2010 May; 24(8):1238-9. PubMed ID: 20421748
    [No Abstract]   [Full Text] [Related]  

  • 78. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.
    Orkin C; Sadiq ST; Rice L; Jackson F;
    HIV Med; 2010 Mar; 11(3):187-92. PubMed ID: 19780860
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.
    Hughes S; Hughes A; Brothers C; Spreen W; Thorborn D;
    Pharm Stat; 2008; 7(2):121-9. PubMed ID: 17534855
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Homogeneous fluorescence detection method for human leukocyte antigen-DR typing following polymerase chain reaction amplification with sequence-specific primer.
    Okamoto N; Lee A; Kano T; Lee TD
    Anal Biochem; 1994 Sep; 221(2):340-7. PubMed ID: 7810876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.